EQS-News: Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange

NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION
OR ANNOUNCEMENT WOULD BE UNLAWFUL

Press Release 

Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange

• Business model focused on innovative radiopharmaceuticals for the diagnosis and therapy (“theranostics”) of various indications
• Institutional environment characterized by high market growth and intense M&A activity
• IPO as a strategic step to secure short- and long-term financing
• Lead candidate PentixaFor already in Phase III
• Commercial rights to over 20 investigator-initiated studies (IIS) for accelerated pipeline development

Berlin and Würzburg, Germany, September 12, 2024 – Pentixapharm Holding AG (“Pentixapharm”) is…